Gene By Gene Rejects BRCA1/2 Patent Infringement Claims by Myriad Genetics, Inc. (MYGN) and Joins Ambry Genetics to Sue Myriad for Violating Federal Antitrust Laws
8/15/2013 7:12:46 AM
More...
|
Ambry Genetics Sues Myriad Genetics, Inc. (MYGN) for Violating Federal Antitrust Laws
8/6/2013 6:38:10 AM
More...
|
Ambry Genetics Reaffirms Status as Worldwide Leader in Hereditary Cancer Testing With New Renal, Pancreatic and PGL-PCC Panels
8/1/2013 11:24:55 AM
More...
|
Ambry Genetics Will Vigorously Defend Against BRCA1 and BRCA2 Gene Patent Infringement Suit
7/11/2013 10:24:04 AM
More...
|
Myriad Genetics, Inc. (MYGN) Sues Ambry Genetics to Thwart Rival Cancer Test
7/10/2013 8:13:45 AM
More...
|
Ambry Genetics Launches BRCA1/2: Single Genes and NGS Panel Offerings
6/14/2013 10:20:06 AM
More...
|
Ambry Genetics Launches FFPE Somatic Variant Profiling Services Developed in Collaboration With Illumina, Inc. (ILMN)
4/4/2013 11:31:34 AM
More...
|
Ambry Genetics Initiates Fluidigm Corporation-Based Genomic Research Services for Gene Expression, SNP Genotyping and Sample Prep for Targeted Sequencing
4/12/2012 10:17:56 AM
More...
|
Ambry Genetics Introduces "First-Step Exome™" Sequencing Test
3/27/2012 7:42:10 AM
More...
|
Ambry Genetics Reports Specific Results from Clinical Diagnostic Exome™ Testing of Patients at Kennedy Krieger Institute
2/29/2012 7:04:51 AM
More...
|
|